PDE5A and benign prostatic hyperplasia: This population of men had significantly lower documented diagnosis of elevated prostate-specific antigen and higher percentage of benign prostatic hyperplasia compared to men not treated with PDE-5 inhibitors (Chavez et al., 2013).